drugset / Trial / NCT00529750
Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
RandomizedParallel-groupDouble-blindTreatment
Summary
Primary: * To evaluate the impact of irbesartan on endothelial function in hypertensive patients with metabolic syndrome. Secondary: * To evaluate the oxidative stress status in patients with hypertension with metabolic syndrome. * To correlate the oxidative stress status with endothelial function in these patients. * To evaluate the effect of irbesartan on the oxidative stress stage in patients with metabolic syndrome and to correlate it with the effect on endothelial function . * To correlate the change in endothelial function and oxidative stress stage with the change of arterial pressure levels.
Timeline
- Start
- 2002-07
- Primary completion
- 2005-01
- Completion
- 2005-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atenolol | Other / unclassified | 50 mg | Oral |
| Subject | Irbesartan | Small molecule | 150 mg | Oral |